Exponent, Inc. — Form 10-Q Summary
Reporting period: The filing covers the quarter ended September 27, 2013, and the nine months ended September 27, 2013, with comparisons to 2012. This conflicts with the request metadata identifying “2012 Q3”; the filing itself is for 2013 Q3.
Business context: Exponent provides multidisciplinary engineering and scientific consulting. Its segments are Engineering and other scientific, and Environmental and health. Financial statements are unaudited; amounts below are in millions unless noted.
Key financial results
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $75.2 | $73.3 | $223.4 | $219.7 |
| Revenue before reimbursements | $70.1 | $66.7 | $211.0 | $201.5 |
| Operating income | $15.2 | $14.7 | $43.6 | $43.9 |
| Net income | $11.1 | $10.2 | $29.9 | $28.8 |
| Diluted EPS | $0.79 | $0.72 | $2.13 | $2.01 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $33.8 | $21.6 |
Q3 EBITDA was $18.8 million, or 26.8% of revenue before reimbursements, versus $17.4 million and 26.1% in 2012. Nine-month EBITDA was $52.9 million, or 25.1% of revenue before reimbursements, versus $50.5 million and 25.1%.
At September 27, 2013, cash and cash equivalents were $121.7 million and short-term investments were $13.3 million, totaling $135.0 million. Current assets were $235.0 million and current liabilities $58.9 million. Total liabilities were $93.8 million; the balance sheet reports no debt. Nine-month capital expenditures were $4.6 million. Financing cash outflows included $21.7 million for share repurchases and $6.0 million for dividends.
Changes and operating drivers
- Q3 revenue increased 2.6%; revenue before reimbursements rose 5%. Net income increased 8.5% and diluted EPS rose from $0.72 to $0.79.
- Nine-month revenue increased 1.7%, while operating income declined slightly from $43.9 million to $43.6 million; net income increased 4.1%.
- Engineering and other scientific revenue increased 6.3% in Q3 and 2.9% year to date. Environmental and health revenue declined 6.9% in Q3 and 1.4% year to date, reflecting reduced activity on major investigations.
- Q3 billable hours increased 2% overall, but utilization declined to 72% from 74%; technical full-time equivalent staff increased 5% to 726. Compensation and related expenses rose 5.2% in Q3 and 5.5% year to date.
- Reimbursable expenses declined 21.9% in Q3 and 31.9% year to date, mainly due to lower project costs in defense technology development. Nine-month defense technology product sales fell to $0.5 million from $2.9 million.
- Operating cash flow improved primarily because accounts receivable declined, compared with an increase in the prior-year period. Cash and short-term investments were broadly stable versus year-end 2012.
Outlook, risks, and unusual items
- Management expects some major investigations to step down as projects progress, and anticipates lower activity in defense technology development amid constrained defense spending and U.S. force reductions in Afghanistan. No numerical earnings or revenue guidance is provided.
- Management expects compensation, other operating expenses, and G&A to rise as it recruits and invests in personnel, facilities, business development, and staff development. It believes available liquidity and operating cash flows will meet requirements for at least 12 months.
- The company recognized $1.4 million of revenue in the first nine months of 2013, upon receipt of payment, for services provided to a foreign client in Q4 2012.
- Deferred-compensation plan asset value increases generated matching compensation expense and other income: $1.9 million in Q3 and $4.1 million year to date. These offsetting entries affected reported expenses and other income.
- A lawsuit related to hiring employees from another consulting firm is in discovery; no trial date or specific damages amount is stated. The company intends to defend the case and believes it will not materially adversely affect financial condition, though ultimate liability cannot be determined.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting. The filing states there were no material changes to previously disclosed risk factors.
Investor verification priorities
- Confirm the intended period: the supplied metadata says 2012 Q3, but this filing reports Q3 2013.
- Assess the sustainability of consulting demand, utilization, and the expected decline in major-investigation and defense-related work.
- Review the Environmental and health segment’s declining revenue and utilization, and the timing and collectability of client receivables.
- Distinguish recurring operating performance from deferred-compensation valuation effects and the prior-period foreign-client revenue recognition.
- Monitor litigation developments, planned repurchases and dividends, and the remaining $34.8 million repurchase authorization.